Aphton (NASDAQ:APHT)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Aphton Charts. Click Here for more Aphton Charts.](/p.php?pid=staticchart&s=N%5EAPHT&p=8&t=15)
Aphton Corporation (NASDAQ:APHT), a biotechnology
company focused on the development of immunotherapies for the
treatment of cancer, announced today that Patrick Mooney, M.D.,
Chairman and Chief Executive Officer, will present an overview of the
Company at the upcoming Rodman & Renshaw Techvest 7th Annual
Healthcare Conference to be held at the Palace Hotel in New York City.
Dr. Mooney's presentation will be on Tuesday, November 8th at 8:40
a.m. ET. A live audio webcast of the presentation can be accessed by
visiting the Rodman & Renshaw conference website at
http://wsw.com/webcast/rrshq7/apht/. A replay of the presentation will
begin 3 hours after the actual presentation and will be available for
30 days.
About Aphton
Aphton Corporation, headquartered in Philadelphia, Pennsylvania is
a clinical stage biopharmaceutical company focused on developing
targeted immunotherapies for cancer. Aphton's products seek to empower
the body's own immune system to fight disease. Through the acquisition
of Igeneon AG in March 2005, Aphton acquired late-stage products,
IGN101, a cancer vaccine designed to induce an immune response against
EpCAM positive tumor cells, and IGN311, a fully humanized antibody
against the Lewis Y antigen. Aphton has strategic alliances with Xoma
for treating gastrointestinal and other gastrin-sensitive cancers
using anti-gastrin monoclonal and other antibodies; and Daiichi Pure
Chemicals for the development, manufacturing and commercialization of
gastrin-related diagnostic kits. Aphton's most advanced product,
Insegia(TM), targets the hormone gastrin 17 in an attempt to treat
gastrointestinal cancers. For more information about Aphton or its
programs please visit Aphton's website at www.aphton.com.
Safe Harbor
This information is qualified in its entirety by cautionary
statements and risk factor disclosure contained in Aphton's Securities
and Exchange Commission filings, including Aphton's report on Form
10-K filed with the Commission on March 16, 2005. Aphton wishes to
caution readers that certain risks and uncertainties may have affected
and could in the future affect the drug development process and
Aphton's business and could cause actual results to differ materially
from Aphton's beliefs and expectations. These risk factors include,
but are not limited to: (1) Aphton's ability to fund the further
development of its research and development programs; (2) Aphton's
ability to successfully identify and consummate opportunities to
broaden and progress its research and development pipeline; (3)
scientific developments regarding immunotherapies; (4) Aphton's
ability to successfully integrate Igeneon's operations and product
portfolio with Aphton's operations and product portfolio; and (5) the
actual design, results and timing of preclinical and clinical studies
for Aphton's products and product candidates.